Update on reshaping the organisation of the European Medicines Agency
Work on reshaping the organisation of the European Medicines Agency to prepare it for the future is proceeding to plan.
From today, 1 August 2013, the Agency's management team will begin transitioning the Agency to a new organisational structure designed to better support the European medicines network and work of the Agency's scientific committees, to better share data held by the Agency, and to better meet needs of the Agency's stakeholders.
The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014. In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.
As previously announced, the main change is the creation of four new divisions dealing with medicines for human use, focused on:
- support to the research-and-development phase;
- medicine evaluation and lifecycle management;
- procedure management and business data;
- inspections and pharmacovigilance.
The current entities responsible for veterinary medicines and horizontal activities remain unchanged.
Details of the new organisational structure, together with the confirmed leadership team, will be announced in mid-September.